サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：家族性高コレステロール血症治療の世界市場（2022年～2029年）
市場調査レポート
商品コード
1078231

家族性高コレステロール血症治療の世界市場（2022年～2029年）

Global Familial Hypercholesterolemia Treatment Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 185 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
家族性高コレステロール血症治療の世界市場（2022年～2029年）
出版日: 2022年05月25日
発行: DataM Intelligence
ページ情報: 英文 185 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の家族性高コレステロール血症治療市場を調査しており、市場の概要、市場規模や予測、動向、成長要因および課題、顧客情勢、薬剤タイプ・適応症タイプ・流通チャネル・地域別の分析、さら企業プロファイルなどを提供しています。

目次

第1章 家族性高コレステロール血症治療市場の調査手法と範囲

  • 調査手法
  • 調査の目的と調査範囲

第2章 家族性高コレステロール血症治療薬市場：市場の定義と概要

第3章 家族性高コレステロール血症治療薬市場：エグゼクティブサマリー

  • 薬剤タイプ別の市場内訳
  • 適応症タイプ別の市場内訳
  • 流通チャネル市の場内訳
  • 地域別の市場内訳

第4章 家族性高コレステロール血症治療市場：市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 家族性高コレステロール血症治療市場：業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • アンメットニーズ

第6章 家族性高コレステロール血症治療市場：COVID-19分析

  • 市場へのCOVID-19の影響分析
    • COVID-19前の市場シナリオ
    • 現在のCOVID-19市場シナリオ
    • COVID-19後または将来のシナリオ
  • COVID-19における価格変動
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 家族性高コレステロール血症治療薬市場：薬剤タイプ別

  • イントロダクション
  • 薬剤タイプ別の市場規模分析、および前年比成長分析
  • 薬剤タイプ別の市場魅力指数
    • スタチン
    • コレステロール吸収阻害剤とスタチンの組み合わせ
    • エゼチミブ（ゼチア）
    • PCSK9阻害剤
    • フィブラート
    • オメガ3脂肪酸サプリメント
    • その他

第8章 家族性高コレステロール血症治療薬市場：適応症タイプ別

  • イントロダクション
  • 適応症タイプ別の市場規模分析、および前年比成長分析
  • 適応症タイプ別の市場魅力指数
    • ヘテロ接合型家族性高コレステロール血症
    • ホモ接合型家族性高コレステロール血症

第9章 家族性高コレステロール血症治療薬市場：流通チャネル別

  • イントロダクション
    • 流通チャネル別の市場規模分析、および前年比成長分析
    • 流通チャネル別の市場魅力指数
  • 病院薬局
    • イントロダクション
    • 市場規模分析（2020年～2029年、および2021年～2029年）
  • 小売薬局
  • その他

第10章 家族性高コレステロール血症治療薬市場：地域別

  • イントロダクション
    • 地域別の市場規模分析（2020年～2029年、および2021年～2029年）
    • 地域別の市場魅力指数
  • 北米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 薬剤タイプ別の市場規模分析、および前年比成長分析
    • 適応症タイプ別の市場規模分析、および前年比成長分析
    • 流通チャネル別の市場規模分析、および前年比成長分析
    • 国別の市場規模分析、および前年比成長分析
  • 欧州
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 薬剤タイプ別の市場規模分析、および前年比成長分析
    • 適応症タイプ別の市場規模分析、および前年比成長分析
    • 流通チャネル別の市場規模分析、および前年比成長分析
    • 国別の市場規模分析、および前年比成長分析
  • 南米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 薬剤タイプ別の市場規模分析、および前年比成長分析
    • 適応症タイプ別の市場規模分析、および前年比成長分析
    • 流通チャネル別の市場規模分析、および前年比成長分析
    • 国別の市場規模分析、および前年比成長分析
  • アジア太平洋
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 薬剤タイプ別の市場規模分析、および前年比成長分析
    • 適応症タイプ別の市場規模分析、および前年比成長分析
    • 流通チャネル別の市場規模分析、および前年比成長分析
    • 国別の市場規模分析、および前年比成長分析
  • 中東とアフリカ
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 薬剤タイプ別の市場規模分析、および前年比成長分析
    • 適応症タイプ別の市場規模分析、および前年比成長分析
    • 流通チャネル別の市場規模分析、および前年比成長分析

第11章 家族性高コレステロール血症治療市場：競合情勢

  • 主な発展と戦略
  • 企業シェア分析
  • 製品のベンチマーク

第12章 家族性高コレステロール血症治療市場：企業プロファイル概要

  • Novartis AG
    • 企業概要
    • 製品ポートフォリオ・種類
    • 主要ハイライト
    • 財務概要
  • Amryt Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Regeneron Pharmaceuticals
  • Amgen Inc
  • Daiichi Sankyo Company Limited
  • Esperion Therapeutics
  • Viatris Inc.
  • Kowa Pharmaceuticals America, Inc.
  • Merck & Co., Inc.

第13章 家族性高コレステロール血症治療薬市場：DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次
Product Code: DMPH5154

Market Overview

The global familial hypercholesterolemia treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Familial hypercholesterolemia is a genetic disease that runs in families. It raises LDL (bad) cholesterol levels dramatically. The disease starts at birth and can lead to heart attacks at a young age.

Market Dynamics

The factors influencing the familial hypercholesterolemia treatment market are the increasing FDA approvals and demand for familial hypercholesterolemia treatment and the growing prevalence of familial hypercholesterolemia.

The increasing FDA approvals and demand for familial hypercholesterolemia treatment are expected to drive the market growth

Familial hypercholesterolemia is a genetic disease that runs in families. It raises LDL (bad) cholesterol levels dramatically. The disease starts at birth and can lead to heart attacks at a young age. LDL cholesterol levels of over 190 mg/dL in adults (and over 160 mg/dL in children) are among the most common signs of FH. Furthermore, most FH people have a family history of early heart disease or heart attacks. Routine blood cholesterol screening can reveal elevated LDL levels in some cases.

The use of novel therapies as an adjunctive treatment for HoFH has been approved. Lomitapide, a microsomal triglyceride transfer protein inhibitor, can lower LDL-C by up to 46 percent in people over 18. In addition, injectable mipomersen, an antisense RNA therapy, is approved in the United States for children as young as 12 years old and can lower LDL-C by up to 25%. Monoclonal antibodies to PCSK9 are being touted as a new treatment option for FH. Moreover, the increasing FDA approvals are expected to drive market growth. For instance, on April 1st, 2021, Praluent (alirocumab) injection was approved by the Food and Drug Administration (FDA) for adult patients with homozygous familial hypercholesterolemia (HoFH). This genetic condition causes severely high cholesterol. Praluent isn't meant to be used on its own; it's meant to be combined with other HoFH treatments.

Limitations associated with familial hypercholesterolemia disease are expected to hamper the market growth

FH is frequently misdiagnosed and mistreated, especially in children. 10 Primary care providers bear the burden of early FH diagnosis. They have a unique opportunity to improve FH detection and management. 11 The National Heart, Lung, and Blood Institute, American Academy of Pediatrics, American Heart Association, National Lipid Association, and American College of Cardiology all recommend universal lipid screening in children aged 9 to 11 years, which has the potential to significantly improve case finding. Moreover, there are currently no long-term studies in children with FH that show a reduction in vascular events when LDL-C lowering treatment is started early. According to the study, children with FH have significantly greater carotid intimamedia thickness than their unaffected siblings, which can be detected as early as 8 to 10 years old.

COVID-19 Impact Analysis

Patients with familial hypercholesterolemia (FH) are more likely to develop COVID-19 complications during the infection's acute phase and for a long time afterward. Because the level of low-density lipoprotein cholesterol (LDL-C) in FH patients is elevated from birth and correlates with the degree of systemic endothelial dysfunction, both heterozygous FH (HeFH) and, in particular, homozygous FH (HoFH) patients have a dysfunctional endothelium that is vulnerable to further damage from the direct viral attack and the hyper-inflammatory response typical of severe COVID-19. The use of statins in patients with COVID-19 has been beneficial in the past. Therefore, the focus on FH patients should be on lowering LDL-C levels effectively, as this is the root cause of the expected increased vulnerability to COVID-19 infection. During the COVID pandemic, continued use of statins and other lipid-lowering therapies should be encouraged to reduce the risk of COVID-19-related cardiovascular complications. Hence, the covid-19 is expected to positively impact the market growth.

Segment Analysis

Based on drugs, the statins segment is expected to drive the market growth in the forecast period

Statins are microorganism-derived drugs that significantly reduce cholesterol synthesis in cells by inhibiting the enzyme HMG-CoA reductase's activity. Statins, on the other hand, lower cholesterol levels in the blood by increasing the number of high-affinity receptors that recognize plasma LDL and decreasing the rate of VLDL synthesis in the liver. This explains why these drugs have a minor triglyceride-lowering effect. The efficacy of statins in lowering plasma cholesterol levels is comparable to that of bile acid-binding polymers, but it is superior to that of fibrates and nicotinic acid. Statins have a better tolerability profile than the other two drugs, but they are less effective at lowering plasma triglycerides and increasing HDL cholesterol levels. At their maximum approved doses, the strongest statins, rosuvastatin, and atorvastatin, can reduce LDLc levels by 50-60%. Moreover, the FDA approvals of this drug are expected to boost its market growth. For instance, on 22nd December 2021, the FDA approved Leqvio (inclisiran) injection for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional low-density lipoprotein lowering in addition to diet and maximally tolerated statin therapy.

Geographical Analysis

North America region is expected to hold the largest market share in the global familial hypercholesterolemia treatment market

The growing prevalence of familial hypercholesterolemia and increasing FDA approvals in this region is expected to drive the market growth.

The prevalence of probable/definite FH in the United States was estimated at 0.40 percent (95 percent confidence interval [CI], 0.32-0.48), or 1 in 250 people (95 percent CI, 1 in 311 to 209). This means that 834,500 adults in the United States have FH. According to studies, the prevalence of heterozygous FH in the general population in the United States and worldwide is 1 in 250.

Moreover, on 23rd December 2021, The US Food and Drug Administration (FDA) approved Inclisiran (Leqvio) for lowering LDL-C in patients with atherosclerotic cardiovascular disease or heterozygous hypercholesterolemia.

Competitive Landscape

The global Familial Hypercholesterolemia Treatment Market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Amryt Pharmaceuticals, Inc., Novartis AG, AstraZeneca Plc., Regeneron Pharmaceuticals, Sanofi S.A., Amgen Inc., Daiichi Sankyo Company Limited, Esperion Therapeutics, Viatris Inc., Kowa Pharmaceuticals America, Inc. and Merck & Co., Inc.

Novartis AG

Overview: Novartis International AG, based in Basel, Switzerland, is a multinational pharmaceutical corporation. It is one of the world's largest pharmaceutical corporations. The company was founded in 1996.

Product Portfolio: LEQVIO (inclisiran) is an injectable prescription medicine used in adults who need additional lowering of "bad" cholesterol (LDL-C) and have heterozygous familial hypercholesterolemia (HeFH).

Key Development: On 23rd December 2021, The US Food and Drug Administration (FDA) approved Novarti's Inclisiran (Leqvio) to lower LDL-C in patients with atherosclerotic cardiovascular disease heterozygous hypercholesterolemia.

Why Purchase the Report?

Visualize the composition of the global familial hypercholesterolemia treatment market segmentation by drug type, indication type, and distribution channel, highlighting the key commercial assets and players.

identify commercial opportunities in global familial hypercholesterolemia treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global familial hypercholesterolemia treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global familial hypercholesterolemia treatment market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Familial Hypercholesterolemia Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Familial Hypercholesterolemia Treatment Market- Market Definition and Overview

3. Familial Hypercholesterolemia Treatment Market- Executive Summary

  • 3.1. Market Snippet By Drug Type
  • 3.2. Market Snippet By Indication Type
  • 3.3. Market Snippet By Distribution Channel
  • 3.4. Market Snippet By Region

4. Familial Hypercholesterolemia Treatment Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. The increasing FDA approvals and demand for familial hypercholesterolemia treatment
    • 4.1.2. Restraints:
      • 4.1.2.1. Limitations associated with familial hypercholesterolemia disease
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Familial Hypercholesterolemia Treatment Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs

6. Familial Hypercholesterolemia Treatment Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Familial Hypercholesterolemia Treatment Market- By Drug Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 7.3. Market Attractiveness Index, By Drug Type
    • 7.3.1. Statins
      • 7.3.1.1.1. Introduction
      • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 7.3.1.1.3. Atorvastatin (Lipitor)
      • 7.3.1.1.4. Fluvastatin (Lescol XL)
      • 7.3.1.1.5. Lovastatin (Altoprev)
      • 7.3.1.1.6. Pitavastatin (Livalo, Zypitamag)
      • 7.3.1.1.7. Pravastatin (Pravachol)
      • 7.3.1.1.8. Rosuvastatin (Crestor, Ezallor)
      • 7.3.1.1.9. Simvastatin (Zocor)
    • 7.3.2. Combination cholesterol absorption inhibitor and statin
    • 7.3.3. Ezetimibe (Zetia)
    • 7.3.4. PCSK9 inhibitors
    • 7.3.5. Fibrates
    • 7.3.6. Omega-3 fatty acid supplements
    • 7.3.7. Others

8. Familial Hypercholesterolemia Treatment Market-By Indication Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
  • 8.3. Market Attractiveness Index, By Indication Type
    • 8.3.1. Heterozygous familial hypercholesterolemia
      • 8.3.1.1.1. Introduction
      • 8.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.3.2. Homozygous familial hypercholesterolemia

9. Familial Hypercholesterolemia Treatment Market- By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Other

10. Familial Hypercholesterolemia Treatment Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Familial Hypercholesterolemia Treatment Market- Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Familial Hypercholesterolemia Treatment Market- Company Profiles

  • 12.1. Novartis AG*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Amryt Pharmaceuticals, Inc.
  • 12.3. AstraZeneca Plc
  • 12.4. Regeneron Pharmaceuticals
  • 12.5. Amgen Inc
  • 12.6. Daiichi Sankyo Company Limited
  • 12.7. Esperion Therapeutics
  • 12.8. Viatris Inc.
  • 12.9. Kowa Pharmaceuticals America, Inc.
  • 12.10. Merck & Co., Inc.

LIST NOT EXHAUSTIVE

13. Familial Hypercholesterolemia Treatment Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us